Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 1-Year Low - Here's Why

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $36.49 and last traded at $36.68, with a volume of 157824 shares changing hands. The stock had previously closed at $36.84.

Analyst Upgrades and Downgrades

Several research analysts recently commented on AMPH shares. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of "Hold" and a consensus target price of $60.33.

Amphastar Pharmaceuticals Stock Up 0.8 %

The stock has a fifty day moving average price of $45.02 and a two-hundred day moving average price of $44.45. The company has a market cap of $1.79 billion, a price-to-earnings ratio of 12.38, a P/E/G ratio of 0.87 and a beta of 0.78. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the transaction, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the business's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the transaction, the director now directly owns 30,471 shares of the company's stock, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,533 shares of company stock valued at $1,987,482 in the last quarter. Company insiders own 27.10% of the company's stock.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in AMPH. TD Asset Management Inc grew its stake in shares of Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company's stock worth $67,663,000 after buying an additional 680,976 shares during the last quarter. Boston Trust Walden Corp bought a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at $26,189,000. Millennium Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 84.6% in the second quarter. Millennium Management LLC now owns 738,748 shares of the company's stock worth $29,550,000 after acquiring an additional 338,653 shares during the period. Epoch Investment Partners Inc. raised its stake in Amphastar Pharmaceuticals by 35.1% during the second quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock worth $43,154,000 after buying an additional 280,390 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at about $9,085,000. 65.09% of the stock is owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.